清冠一號團隊攜手訊聯外泌體及AI智慧研發技術，推出全新功能性中草藥外泌體「清泌一號」，左起為訊聯基因數位總經理康清原、台灣中醫病理學醫學會副秘書長張慈文醫師、訊聯集團董事長蔡政憲博士、國家中醫藥研究所蔡耿彰教授、中草藥農葉先生、訊聯細胞智藥總經理李黛苹博士。
疫情期間熱銷60餘國的「清冠一號」，助全球人類重拾健康，中草藥對抗COVID-19的藥效與機轉，在AI模擬分析下得以完全解鎖，讓中藥的科學性跟信賴感揚名國際，也讓台灣中草藥2022年產值衝上百億台幣！今年，清冠一號團隊再出擊，攜手訊聯外泌體及AI智慧研發技術，推出全新功能性中草藥外泌體「清泌一號」，開發具備保濕、抑菌、抗發炎三大功效外泌體新複方，展現中醫藥、外泌體先端製程與AI結合的創新能量，被視為帶動中醫藥與農業再生醫學化的全球新契機！
訊聯集團董事長蔡政憲博士展示「清泌一號」。
回顧2020年，清冠一號(NRICM101)僅用短短5個月就成功研發問世，訊聯AI智慧研發團隊24小時內完成中草藥成份、逾3萬多個人體與COVID-19蛋白質標的大量比對分析，協助解釋並優化其療效，相關成果發表於《Biomedicine》等國際期刊，以科學展現台灣中醫藥的研發實力。
訊聯集團董事長蔡政憲博士展示的「清泌一號」，結合AI模擬與科學分析，融合中西醫優勢，有望成為繼「清冠一號」後，推動台灣中醫藥外銷的最新代表作。
國家中醫藥研究所蔡耿彰教授表示，「中藥外泌體研發」是蘇奕彰所長繼「中藥新藥研發」的另一項台灣中醫藥發展的重大策略，「清冠一號」讓全球重新認識中醫藥的價值，「清泌一號」則進一步展現中草藥的創新與跨域能量。外泌體技術近年於再生醫學、免疫調節、醫美與皮膚修復領域備受矚目，「清泌一號」結合AI模擬與科學分析，融合中西醫優勢，有望成為繼「清冠一號」後，推動台灣中醫藥外銷的最新代表作。
「清泌一號」是清冠一號團隊與訊聯外泌體及AI智慧研發驅動的「第一帖」功能性中草藥外泌體，首波應用聚焦於皮膚、毛髮與私密處保養，並可延伸至多種應用。
台灣中醫病理學醫學會副秘書長張慈文醫師表示，外泌體就是中醫『鮮品』的現代詮釋，效果更直接且穩定。中西醫雙修的張慈文醫師指出，中醫普遍認為「鮮品」蘊含藥材最自然的精華與活性成分，價值極高；但過去受限於產地與運輸而難以普及。現代科技讓中草藥外泌體重現中醫藥材鮮用或帶汁使用的鮮品智慧。
「清泌一號」是清冠一號團隊與訊聯外泌體及AI智慧研發驅動的「第一帖」功能性中草藥外泌體，首波應用聚焦於皮膚、毛髮與私密處保養，並可延伸至多種應用。
「清泌一號」是台灣首度運用在地中草藥外泌體的創新嘗試，也為台灣農業產銷失衡找到一個突破口。張慈文醫師指出：「農民種東西，都是師傅；但賣的時候就變成師仔(徒弟)」，因此包括她和清冠一號團隊在內的多位中醫專家，積極投入中藥材從源頭的種植與馴化研究，實踐「以醫領藥、以藥帶農」的新使命，與農民共同打造「在地可耕、全球可銷」的中草藥供應鏈。此次選用的曇花與金錢薄荷皆以安全、無毒農法栽種，證明中藥材可在台灣成功馴化並實現高附加價值的轉化，進一步透過國際接軌，將「清泌一號」推向全球，打造台灣功能性中草藥特色品牌，未來一提到「功能性中草藥」就想到台灣。
為追求最終、最佳功效，以「清泌一號」配方為基底，結合哺乳類外泌體，針對私密處高效保養，設計出ExoSecret。
訊聯細胞智藥(7808)董事長蔡政憲博士表示，「清泌一號」是清冠一號團隊與訊聯外泌體及AI智慧研發驅動的「第一帖」功能性中草藥外泌體，首波應用聚焦於皮膚、毛髮與私密處保養，並可延伸至多種應用。蔡政憲說，為追求「最終、最佳功效」，以「清泌一號」配方的黃金比例，針對私密處高效保養再結合哺乳類外泌體，設計出ExoSecret；針對毛髮強健，新品ExoRoots更加上以AI功能預測分析選出的IGF-1活性專利因子，目前已申請專利。由於IGF-1在促進毛髮生長與膠原蛋白生成的協同功效上表現優異，ExoRoots宛如升級版的中西醫合璧複方外泌體。
以「清泌一號」配方為基底，加上AI功能預測分析選出的IGF-1活性專利因子，專為毛髮強健打造出新品ExoRoots，目前已申請專利。
此外，訊聯建立跨物種外泌體巨量資料庫，訓練「外泌體功能預測AI模型」，涵蓋數百種miRNA、基因定序、蛋白質、胜肽等資料，能為客戶創造跨物種外泌體的多元運用商機。從推動Exosome Foundry(外泌體全球研發代工)至今，已促進寵物、醫療保健、光電雷射、妝品製造等18業態導入再生醫學技術，這次更擴大到中醫藥與農業再生醫學化，為產業創造更高附加價值。
根據Persistent Market Research報告，全球中草藥市場規模預計到2033年將達約500億美元，年複合成長率達5.1%。台灣中草藥生產過去仰賴進口，製劑出口單價卻可高出原料進口價甚至15倍(統計至2016年)，展現產業高度潛力。如今，中草藥原料結合外泌體先端製程、AI輔助的創新模式，開發成外泌體再生醫學產品與應用，產值甚至可翻百倍、千倍，未來前景可觀。「清泌一號」有望成為繼「清冠一號」之後，又一具有策略意義的產業新星，推動台灣中醫藥邁向全球市場。
[BIONET Therapeutics Corp. X NRICM101 Team] — Launch of “ExoHerb”: The First Functional Herbal Exosome to Drive the Medicalization of Agriculture
The internationally acclaimed team behind NRICM101 ("Qingguan No.1") has joined forces with BIONET Therapeutics Corp. to unveil their latest innovation: "ExoHerb," a functional herbal-derived exosome developed through AI-assisted research. This breakthrough product is set to accelerate the integration of Traditional Chinese Medicine (TCM) and regenerative medicine, while also promoting the transformation of Taiwan's agricultural resources into high-value medical applications.
During the COVID-19 pandemic, NRICM101 was exported to over 60 countries, helping people worldwide regain health. Its efficacy against the virus, clarified through AI simulation analysis, showcased the scientific foundation of Chinese herbal medicine and elevated Taiwan's herbal product industry to over NT$10 billion by 2022. Building on this success, the same team has partnered with BIONET Corp.’s exosome platform and AI-powered R&D to develop ExoHerb—a new herbal-derived exosome formula with moisturizing, antibacterial, and anti-inflammatory properties. ExoHerb symbolizes the convergence of TCM, cutting-edge exosome purification, and AI analytics, positioning Taiwan as a leader in global herbal biotech innovation.
Back in 2020, the formulation of NRICM101 (Qingguan No.1) took just five months. BIONET Corp.'s AI R&D team conducted 24-hour screening of herbal ingredients against over 30,000 human-COVID protein targets, validating and enhancing its clinical efficacy. Results were published in international journals such as Biomedicine, demonstrating Taiwan’s strength in TCM R&D.
Prof. Keng-Chang Tsai from the National Research Institute of Chinese Medicine, MOHW, stated that the development of exosome-based TCM represents a major strategic direction following the efforts of Prof. Su Yi-Chang in the area of new herbal drug development in Taiwan. Prof. Tsai emphasized that while NRICM101 helped the world rediscover the value of TCM, ExoHerb further demonstrates the innovation and interdisciplinary strength of herbal medicine. While NRICM101 reintroduced the global community to the value of TCM, ExoHerb exemplifies TCM's interdisciplinary potential. With increasing attention to exosomes in regenerative medicine, immunomodulation, aesthetics, and dermatology, ExoHerb uses AI-based analysis to modernize traditional formulas, making it a strong candidate for Taiwan’s next globally recognized herbal product.
Dr. Chang Tzu-Wen, Deputy Secretary-General of the Taiwan Society for Pathology of Chinese Medicine (TSPCM), stated that exosomes offer a modern interpretation of what TCM calls "fresh essence" – the most natural, bioactive part of herbs. Previously difficult to preserve due to sourcing and transport, these potent elements can now be captured through exosome isolation.
ExoHerb is the first innovation using locally cultivated herbs like Epiphyllum (Night-blooming Cereus) and Plectranthus amboinicus (Cuban oregano), grown with toxin-free methods. This not only revives TCM’s "fresh-use" tradition, but also solves the local agricultural surplus problem. Dr. Chang adds: "Farmers are masters in growing crops but become like apprentices when it comes to selling." To reverse this, she and fellow NRICM101 team members advocate for a "medical-leads-pharma, pharma-drives-agriculture" model, building a TCM supply chain that is both locally cultivatable and globally marketable.
Dr. Chang adds: "Farmers are masters in growing crops but become amateurs when it comes to selling." To reverse this, she and fellow NRICM101 team members advocate for a "medical-leads-pharma, pharma-drives-agriculture" model, building a TCM supply chain that is both locally cultivatable and globally marketable.
According to Dr. Chris Tsai, Chairman of BIONET Therapeutics Corp. (stock code: 7808), ExoHerb is the first TCM functional exosome developed with NRICM101 expertise and BIONET Corp.'s AI-Exosome R&D platform. Its initial applications focus on skin, hair, and intimate care. For example, ExoSecret combines ExoHerb with mammalian exosomes for high-performance intimate care, while ExoRoots is designed for hair health and includes IGF-1 bioactive components identified through AI prediction—with patents filed. IGF-1 is known to promote both hair growth and collagen production, making ExoRoots a next-generation formula integrating Eastern and Western science.
Additionally, BIONET Corp. has developed a cross-species exosome database to train its Exosome Function Prediction AI Model. This dataset spans hundreds of miRNAs, gene sequences, proteins, and peptides, enabling broad commercial applications. Through its Exosome Foundry model, BIONET Corp. has facilitated regenerative medicine adoption in over 18 industries, including pet health, medical devices, cosmetics, and now TCM and agriculture—further raising Taiwan's biotech value.
According to Persistent Market Research, the global herbal medicine market is expected to reach USD 50 billion by 2033, with a CAGR of 5.1%. Historically, Taiwan relied on imports for herbal raw materials, yet exported formulations could command up to 15x the unit price of the imported ingredients (data as of 2016). By integrating exosome technology and AI, this model now has the potential to multiply that value by hundreds or even thousands, opening vast market opportunities. ExoHerb is well positioned to become a strategic next-generation herbal biotech flagship for Taiwan, following the path set by NRICM101.
◆ 瞭解詳情：
◆ 花絮直擊：
